Do you remember the results several years about the sleeping drug that NBIX was trying to get by the FDA? Stock went from 70 to 5. This company is run by a loser. Covering at $35. Don't be shocked to see it slowly creep back down to $2/share.
What we want you to do is get lost and never come back. No one on here want to listen to anything you have to say! Period!
what do you want me to do? If stock goes up, I got nothing to say. See ya at $35 shortly. Biotech bubble popped several months ago, you too greedy to see it.
Called that one. Typical "grave dancer" behavior, comes and gloats when the stock goes down, slinks away when it goes up. Quintessential #$%$.
warned ya folks. biotech bubble is over. down she goes.
It is the macro environment and biotech in particular. Hedge fund redemptions and sovereign wealth funds being forced to sell because of the low price of oil have all contributed to the current stock price and general mood of pessimism. If you look at charts comparing NBIX to the IBB and XBI indices, you see clearly that Neurocrine is outperforming. On a 1 year chart it is up 26.4%, while the IBB and XBI are down 15.3% and 21.9% respectively. On a six month chart NBIX is down 15.5%, while the IBB and XBI are down 30.9% and 41.5% respectively. I just hope Abbvie doesn't make a buyout offer at these low levels.
I don't expect any true earnings from sales/royalties this year, milestones payments will be made and there is a possibility of new partnership money.
It is crazy that this stock has stayed down as much as it has. Multiple upcoming announcements that if positive will make that stock appreciate in value immensely. Plus we are partnered with perhaps one of the worlds finest companies in Abbvie. As most should know they don't take a lot of bad risks. And my favorite part is the huge institutional holding of the shares, I personally have made more $$$ on stocks with large institutional holding percentages than any others, Just my observations. Do your own due diligence research.
As per NBIX's September decline, the 50dma and the the 200dma continue to narrow --- as in all good. Momentum remains low, as does relative strength. Just as in September the stock is oversold having come down to the 40 level. Too many good things this year await to propel Neurocrine higher. Most important will be the beginnings of earnings flow. As a result, Neurocrine will become a completely different animal in the case of the way the company is looked at and perceived. Anyone who chooses to that, may live to regret it. I didn't write the play, but I know the script ........ having observed "that behavior" before in other biotechs on , and about to enter the earnings threshhold. Those that do enter it, go a lot further in in stock appreciation than anyone ever expected them go beforehand. Get ready.
Significant investors looking to buy/add shares have consistently, waited on the side during any NBIX selling pressure, and when the selling pressure abates/subsides, they come in usually late in the day to buy the shares. They haven't abandoned anything. They recognize NBIX is a future star in which an earnings driven market will ultimately seek out and elevate from levels it is now. The pattern should continue.